BATON ROUGE, La., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the fourth quarter and year ended December 31, 2022, after the market closes on February 15, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 16, 2023.
To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through March 16, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13735891.
A live webcast of the call will be accessible through the Company website on the Investor Relations section at http://investors.amedisys.com.
About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 532 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 465,000 patients in need every year, performing more than 11.2 million visits annually. For more information about the Company, please visit: www.amedisys.com.
Contact:
| Nick Muscato | Kendra Kimmons | |
| Amedisys, Inc. | Amedisys, Inc. | |
| Investor Relations | Media Relations | |
| 615.928.5452 | 225.299.3720 | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |

| Last Trade: | US$100.99 |
| Daily Volume: | 0 |
| Market Cap: | US$3.320B |
July 29, 2025 April 23, 2025 February 26, 2025 November 06, 2024 August 21, 2024 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load